VVOS
Vivos Therapeutics, Inc.
+0.01 (+7.70%)0.17USD740K成交股數3.5M市值–本益比(近四季)0.2股價營收比+34.9%營收年增(近四季)2026-11-16下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 5.2M+71% | 5.1M+39% | 6.8M+76% | 3.8M-6% | 3.0M-12% | 3.7M+12% | 3.9M+14% | 4.1M+5% | 3.4M | 3.3M | 3.4M | 3.9M |
| 營業成本 | 2.2M | 2.1M | 2.8M | 1.7M | 1.5M | 3.0M | 1.5M | 1.4M | 100K | 100K | 100K | 100K |
| 毛利 | 3.0M+96% | 3.1M+46% | 3.9M+69% | 2.1M-20% | 1.5M-22% | 2.1M+20% | 2.3M+11% | 2.7M+13% | 1.9M | 1.7M | 2.1M | 2.3M |
| 毛利率 | 57.3% | 59.5% | 58.0% | 55.2% | 50.0% | 56.7% | 60.5% | 65.4% | 56.7% | 52.9% | 61.8% | 60.6% |
| 研發費用 | – | – | – | – | – | – | – | – | 100K | 100K | 100K | 100K |
| 銷售管理費用 | 7.1M | 9.0M | 7.9M | 6.4M | 4.9M | 4.3M | 4.5M | 4.1M | 4.9M | 4.6M | 5.9M | 6.5M |
| 營業利益 | −4.8M+23% | −6.6M+136% | −4.7M+79% | −4.9M+151% | −3.9M+4% | −2.8M-23% | −2.6M-41% | −1.9M-61% | −3.8M | −3.6M | −4.5M | −5.0M |
| 營業利益率 | -93.6% | -128.7% | -69.8% | -127.4% | -129.9% | -75.9% | -68.5% | -47.8% | -110.7% | -110.3% | -133.0% | -129.8% |
| 稅後淨利 | −5.5M+42% | −7.7M+172% | −5.4M+106% | −5.0M+160% | −3.9M+3% | −2.8M+35% | −2.6M-53% | −1.9M+13% | −3.8M | −2.1M | −5.5M | −1.7M |
| 淨利率 | -106.4% | -149.4% | -79.6% | -131.2% | -128.1% | -76.4% | -67.8% | -47.6% | -110.1% | -63.4% | -162.8% | -44.2% |
| 稀釋 EPS | -0.31-31% | -0.52-227% | -0.49+22% | -0.55-8% | -0.45-72% | 0.41-123% | -0.40-91% | -0.60-65% | -1.63 | -1.75 | -4.62 | -1.72 |
| 稀釋股數 | 17.7M | 14.6M | 11.0M | 9.1M | 8.6M | 5.0M | 6.6M | 3.2M | 2.3M | 1.2M | 1.2M | 991K |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 1.8M | 2.1M | 3.1M | 4.4M | 2.3M | 6.3M | 6.3M | 6.9M | 2.6M | 988K | 3.9M | 7.0M |
| 應收帳款 | 1.4M | 1.8M | 2.1M | 1.6M | 718K | 430K | 454K | 395K | 525K | 228K | 327K | 321K |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 24.1M | 25.0M | 25.6M | 26.0M | 11.3M | 15.3M | 15.3M | 15.8M | 11.8M | 10.3M | 13.7M | 17.1M |
| 有息負債 | 366K | 418K | 8.4M | 7.8M | – | 1.2M | 1.2M | 1.2M | – | 1.2M | 1.2M | – |
| 總負債 | 28.1M | 26.3M | 23.1M | 21.5M | 6.9M | 7.3M | 7.7M | 9.5M | 11.2M | 10.3M | 11.6M | 10.1M |
| 股東權益 | −3.8M | −1.1M | 2.5M | 4.6M | 4.4M | 8.0M | 7.7M | 6.3M | 582K | 46K | 2.1M | 7.0M |
| 負債比 | 116.5% | 105.1% | 90.1% | 82.4% | 60.9% | 48.0% | 50.1% | 59.9% | 95.1% | 99.6% | 84.7% | 59.1% |
| 淨現金(現金 − 有息負債) | 1.4M | 1.7M | −5.3M | −3.4M | – | 5.1M | 5.1M | 5.7M | – | −212K | 2.7M | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −6.0M | – | – | −3.8M+51% | – | – | – | −2.5M | – | – | −3.5M |
| 資本支出 | – | 18K | – | – | 122K | – | – | – | 151K | – | – | 239K |
| 自由現金流 | – | −6.0M | – | – | −3.9M+47% | – | – | – | −2.7M | – | – | −3.8M |
| 折舊攤銷 | 510K | 454K | 384K | 306K | 177K | 144K | 146K | 145K | 146K | 150K | 148K | 175K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -117.3% | – | – | -129.9% | – | – | – | -78.0% | – | – | -98.0% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 8.2M
| Appliances | 3.3M | 40.0% | -41.5% |
|---|---|---|---|
| Treatment Centers | 2.2M | 26.6% | – |
| Sponsorship Seminar Other | 1.2M | 14.9% | -37.0% |
| Billing Intelligence Services | 686K | 8.4% | -18.3% |
| VIP | 491K | 6.0% | -80.2% |
| Myofunctional Therapy Services | 337K | 4.1% | -44.7% |
| 服務 小計 | 11.0M | 133.7% | +53.1% |
| 產品 小計 | 6.5M | 79.2% | -17.6% |
| Sleep Testing Services 小計 | 6.0M | 73.7% | +371.2% |
| Tooth Positioners 小計 | 3.2M | 39.2% | +41.2% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 17.4M | +16.0% | −21.2M | -121.4% | -2.07 | −17.6M |
| FY2024 | 15.0M | +8.9% | −11.1M | -74.1% | -2.22 | −13.3M |
| FY2023 | 13.8M | -13.9% | −13.6M | -98.4% | -11.14 | −12.7M |
| FY2022 | 16.0M | -5.1% | −23.8M | -148.8% | -25.90 | −20.5M |
| FY2021 | 16.9M | +29.2% | −20.3M | -120.2% | -0.96 | −18.1M |
| FY2020 | 13.1M | +14.7% | −12.1M | -92.3% | -1.40 | −5.8M |
| FY2019 | 11.4M | – | −10.8M | -94.4% | -0.95 | −5.5M |